Comments
Lupin has received an Establishment Inspection Report (EIR) from the US health regulator for its Pithampur Unit 1 manufacturing facility in Madhya Pradesh. The inspection was conducted in July 2017, the company said in a BSE filing today.
USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection. In November last, Lupin had received a warning letter from the USFDA (US Food and Drug Administration) for its manufacturing facilities in Goa and Pithampur.
Lupin shares were trading up by 3.56 per cent at Rs 813.95.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.